Subcutaneous administration of the sphingosine kinase 2 inhibitor ABC294640 has no metabolic benefits in high fat diet-induced obesity in male mice
Contrary to prior studies, our findings reveal no therapeutic benefit of SphK2 inhibition in diet-induced obesity. These results underscore the importance of tissue and context specificity in targeting the sphingosine kinase pathway and caution against broadly applying SphK2 inhibition as a strategy for treating obesity-associated metabolic dysfunction.
Authors
- Lotte Vanherle (ORCID: https://orcid.org/0000-0002-4864-1347)
- Cecilia Skoug
- João M. N. Duarte (ORCID: https://orcid.org/0000-0001-5984-1574)
- Anja Meißner (ORCID: https://orcid.org/0000-0002-0793-7213)
- Karin G. Stenkula (ORCID: https://orcid.org/0000-0002-0739-1150)
- Claes Fryklund (ORCID: https://orcid.org/0000-0002-2581-8832)
- Lisa Teresa Porschen
Institutions
- Lund University (SE)
Publication Details
- Journal
- Life Sciences
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1016/j.lfs.2025.123952
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00